Table of Contents
A new CMS final rule will prevent federal Medicaid and Children’s Health Insurance Program funding from going toward gender-affirming care for youths, establishing the CMS Medicaid CHIP gender-affirming care rule that takes effect this fall.
What This Rule Actually Blocks
The rule, which Becker’s reviewed Aug. 11, will go into effect Oct. 13. It blocks states from using Medicaid federal matching funds for puberty blockers, gender-affirming hormone therapy and related surgeries, such as mastectomies and vaginoplasties, for those younger than 18. The rule also prevents federal CHIP funds from covering those uses and procedures for those younger than 19.
The Agency’s Stated Rationale
“Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits,” CMS Administrator Mehmet Oz, MD, said in a news release.
The Financial Estimates Behind This CMS Medicaid CHIP Gender-Affirming Care Rule
The agency estimated the rule will lower federal Medicaid spending by roughly $175 million from fiscal 2027 through fiscal 2036, based on real 2027 dollars. In 2023, regulators identified about $31 million in federal and state Medicaid and CHIP spending for these services and patients. Officials said states that had not barred gender dysphoria treatments for children as of 2023 contributed to 76% of that spending.
Transition Provisions Within the Rule
Federal Medicaid and CHIP funding will still be accessible during a tapering-off period of up to six months from when the rule goes into effect for children currently on hormone therapy. The rule does not apply to mental health services.
The Regulatory Timeline Behind This Rule
CMS initially proposed the rule in December 2025. In April 2025, the agency asked state Medicaid agencies to not cover hormone therapies and gender-affirming surgery for youths. In May 2025, federal regulators said they were investigating hospitals across the country that offered gender-affirming care to children.
How Hospitals Have Responded to Federal Scrutiny
Hospitals and health systems nationwide have limited or paused gender-affirming care programs amid federal probes and enforcement actions. Hartford-based Connecticut Children’s Medical Center was the third hospital to settle following Justice Department investigations into this area of care.
Publication and Effective Date of This CMS Medicaid CHIP Gender-Affirming Care Rule
The rule will be published in the Federal Register on Aug. 13, formally starting the countdown toward its Oct. 13 effective date and giving states, hospitals, and Medicaid managed care plans roughly two months to adjust coverage policies and billing practices accordingly.
What State Medicaid Agencies Will Need to Do
States that currently permit Medicaid or CHIP coverage of these services for minors will need to update their coverage policies ahead of the October effective date, particularly given that spending data specifically identified non-compliant states as responsible for the majority of related federal and state spending as of 2023.
What This CMS Medicaid CHIP Gender-Affirming Care Rule Means Going Forward
With the rule set to take effect Oct. 13 and a tapering-off period of up to six months available for children currently receiving hormone therapy, state Medicaid agencies, hospitals, and health plans will need to coordinate transition plans for affected patients before federal funding for these specific treatments ends. Given the rule’s connection to a broader pattern of federal investigations and hospital settlements already reshaping how health systems approach pediatric gender-affirming care nationally, this policy formalizes at the federal funding level a shift many hospitals had already begun making independently.
What to Watch Going Forward
As the rule moves toward its Oct. 13 effective date, industry observers will likely watch how state Medicaid agencies in states that previously covered these services adjust their programs, and how the six-month tapering-off period is implemented for children already receiving hormone therapy. Given the rule’s connection to ongoing Justice Department hospital investigations and settlements, this CMS Medicaid CHIP gender-affirming care rule may continue to intersect with parallel legal and regulatory actions affecting how hospitals nationwide structure their pediatric care programs going forward.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
